Wei Li

US Patent:

8426402, Apr 23, 2013

Filed:

Feb 4, 2010

Appl. No.:

12/700131

Inventors:

Wei Li - Acton MA, US
Nathan Fishkin - Weymouth MA, US
Robert Zhao - Lexington MA, US
Michael Miller - Framingham MA, US
Ravi Chari - Newton MA, US

Assignee:

ImmunoGen, Inc. - Waltham MA

International Classification:

C07D 519/00
A61K 31/5517
A61K 31/55
A61P 35/00

US Classification:

514219, 540494

Abstract:

The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

US Patent:

8598362, Dec 3, 2013

Filed:

Dec 8, 2011

Appl. No.:

13/315005

Inventors:

Wei Li - Acton MA, US
Robert Yongxin Zhao - Lexington MA, US

Assignee:

ImmunoGen, Inc. - Waltham MA

International Classification:

C07D 401/00

US Classification:

5462781

Abstract:

Processes for the preparation of charged crosslinkers bearing a sulfonic acid moiety are disclosed. These procedures also optionally include methods to convert the resulting products to substantially a single salt form.

US Patent:

8620629, Dec 31, 2013

Filed:

Mar 12, 2010

Appl. No.:

12/723290

Inventors:

Wei Li - Framingham MA, US
John Edward Ciolfi - Wellesley MA, US
Michael I. Clune - Natick MA, US

Assignee:

The Mathworks, Inc. - Natick MA

International Classification:

G06F 17/50
G06F 7/60
G06G 7/48

US Classification:

703 2, 703 1, 703 6

Abstract:

A Discrete Event System model created or provided in a time domain modeling and simulation environment and/or an event domain modeling and simulation environment may be divided into multiple independent regions, e. g. “subgraphs”, to achieve interleaved execution of the components from different domains. The subgraphs are automatically identified by the modeling and simulation environment during the compilation. Each subgraph consists of one or more interconnected event-driven components. Each subgraph is associated with an event calendar that controls the execution of the associated subgraph. Such multiple event calendar design enables multi-domain simulation, where event-driven components modeled by an event domain modeling environment and time-driven components modeled by a time domain modeling environment are simulated in an integrated fashion.

US Patent:

20100227859, Sep 9, 2010

Filed:

May 5, 2008

Appl. No.:

12/598868

Inventors:

Wei LI - Acton MA, US
Jianchang Li - Acton MA, US
Yuchuan Wu - Acton MA, US
Junjun Wu - Billerica MA, US
Rajeev Hotchandani - Watertown MA, US
Steve Yikkai Tam - Wellesley MA, US
Tarek Suhayl - Mansour NY, US
Joseph P. Sypek - Waban MA, US
Iain McFadyen - Medford MA, US

International Classification:

A61K 31/5377
C07D 407/04
A61K 31/343
C07D 413/14
C07D 417/14
A61K 31/497
A61P 19/02
A61P 9/10
A61P 11/06
A61P 35/00
A61P 3/04
A61P 3/10

US Classification:

5142328, 549461, 514468, 544140, 544369, 51425402

Abstract:

The present teachings relate to compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, R4, X, and Y are as defined herein. The present teachings also provide methods of making the compounds of formula I and methods of inhibiting matrix metalloproteinases, in particular, MMP-12, that may be involved in pathological disorders found in mammals, including a human.

US Patent:

20110112180, May 12, 2011

Filed:

Sep 10, 2008

Appl. No.:

12/677511

Inventors:

Zhiwei Jiang - Stow MA, US
Chiang Jia Li - Cambridge MA, US
Wei Li - Wayland MA, US
David Leggett - Milton MA, US

Assignee:

Boston Biomedical, Inc. - Norwood MA

International Classification:

A61K 31/343
C07D 307/92
C12N 5/095
A61P 35/00
A61P 35/02
A61P 35/04
C07D 333/74
A61K 31/381

US Classification:

514443, 549458, 514468, 435375, 549 44

Abstract:

The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical compositions containing such compounds.

US Patent:

20120244171, Sep 27, 2012

Filed:

Feb 15, 2012

Appl. No.:

13/397195

Inventors:

Wei Li - Acton MA, US
Michael Miller - Framingham MA, US
Nathan Fishkin - Weymouth MA, US
Ravi V.J. Chari - Newton MA, US

Assignee:

ImmunoGen, Inc. - Waltham MA

International Classification:

A61K 31/5517
C07K 16/28
A61K 39/395
A61P 35/00
A61P 13/12
A61P 19/08
A61P 31/00
A61P 31/12
A61P 25/28
A61P 1/18
C07D 487/04
A61P 37/00

US Classification:

4241811, 540494, 514219, 5303919

Abstract:

The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VII). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.

US Patent:

20130266596, Oct 10, 2013

Filed:

Feb 22, 2013

Appl. No.:

13/774059

Inventors:

Wei Li - Acton MA, US
Nathan Elliott Fishkin - Weymouth MA, US
Robert Yongxin Zhao - Lexington MA, US
Michael Louis Miller - Framingham MA, US
Ravi V.J. Chari - Newton MA, US

International Classification:

A61K 47/48
A61K 45/06

US Classification:

4241811, 5303919

Abstract:

The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

US Patent:

20130302357, Nov 14, 2013

Filed:

Mar 14, 2013

Appl. No.:

13/826181

Inventors:

Wei Li - Acton MA, US
Nathan Elliott Fishkin - Weymouth MA, US
Robert Yongxin Zhao - Lexington MA, US
Michael Louis Miller - Framingham MA, US
Ravi V.J. Chari - Newton MA, US

International Classification:

C07D 487/04
C07K 16/28
A61K 45/06
A61K 38/07
C07K 5/103
A61K 47/48
A61K 31/5517

US Classification:

4241781, 5303917, 514219, 540494, 514 219, 530330, 514 37, 514 167, 514 177, 514 154, 514 192, 514 193, 514 194, 514 195

Abstract:

The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.